Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...

Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.